RxDoctor Payments DataLook up a doctor →

Richard Scartozzi, MD

Retina Specialist · Danbury, CTNPI 1487688826

Payments from drug & device makers

$693,608in general payments, 2019–2025

Across 157 payments — averaging $4417.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Apellis Pharmaceuticals, Inc.$241K
  • Boehringer Ingelheim$236K
  • Novartis$109K
  • Eyepoint US, Inc.$102K
  • Boehringer Ingelheim International GmbH$5K
  • Vertex$440
  • plus $1K from 11 others
$126in research payments, 2019–2025

Across 2 payments — averaging $62.93 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Boehringer Ingelheim International GmbH$126

What the payments were for

  • Consulting fees$79545%
  • Speaking & faculty fees$18811%
  • Food & beverage$78544%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

Too few retina specialist providers in Connecticutto place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$2,292,376
Medicare patients
1,051
Services billed
13,897

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
ProlensaBromfenac Sodium45$18,917
IlevroNepafenac32$11,897
Bromfenac Sodium45$11,749
LumiganBimatoprost14$8,522
Prednisolone Acetate39$1,400
Brimonidine Tartrate20$1,237
Latanoprost67$857
Ketorolac Tromethamine13$279
Dorzolamide Hcl12$165

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisIlevro$108,552$11,89732 claims
AbbVieLumigan$107$8,52214 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few retina specialist providers in Connecticuton file to place this against a meaningful peer group, so we don't.

Other retina specialist in Danbury

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →